Literature DB >> 20046352

Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder.

Dong-Hwan Yun1, Chi-Un Pae, Antonio Drago, Laura Mandelli, Diana De Ronchi, Ashwin A Patkar, In Ho Paik, Alessandro Serretti, Jung-Jin Kim.   

Abstract

OBJECTIVE: We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment.
METHODS: A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (+/-19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, rs760761 C/T and rs2619522 A/C).
RESULTS: There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors.
CONCLUSION: Although the small number of subjects is an important limitation in our study, DTNBP1 does not seem to be involved in acute antimanic efficacy.

Entities:  

Keywords:  Antimanic agents; Bipolar disorder; Dysbindin; Pharmacogenetics

Year:  2008        PMID: 20046352      PMCID: PMC2796018          DOI: 10.4306/pi.2008.5.2.102

Source DB:  PubMed          Journal:  Psychiatry Investig        ISSN: 1738-3684            Impact factor:   2.505


  26 in total

1.  Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families.

Authors:  Sibylle G Schwab; Michael Knapp; Stephanie Mondabon; Joachim Hallmayer; Margitta Borrmann-Hassenbach; Margot Albus; Bernard Lerer; Marcella Rietschel; Matyas Trixler; Wolfgang Maier; Dieter B Wildenauer
Journal:  Am J Hum Genet       Date:  2002-12-09       Impact factor: 11.025

Review 2.  Identification of molecular mechanisms underlying mood stabilization through genome-wide gene expression profiling.

Authors:  Rulun Zhou; Carlos A Zarate; Husseini K Manji
Journal:  Int J Neuropsychopharmacol       Date:  2005-10-06       Impact factor: 5.176

3.  Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain.

Authors:  M A Benson; S E Newey; E Martin-Rendon; R Hawkes; D J Blake
Journal:  J Biol Chem       Date:  2001-04-20       Impact factor: 5.157

Review 4.  Family, twin, adoption, and molecular genetic studies of juvenile bipolar disorder.

Authors:  Robert R Althoff; Stephen V Faraone; David C Rettew; Christopher P Morley; James J Hudziak
Journal:  Bipolar Disord       Date:  2005-12       Impact factor: 6.744

Review 5.  Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder.

Authors:  Martin Alda; Paul Grof; Guy A Rouleau; Gustavo Turecki; L Trevor Young
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-07       Impact factor: 5.067

Review 6.  Neuropsychological dysfunction in bipolar affective disorder: a critical opinion.

Authors:  Jonathan Savitz; Mark Solms; Rajkumar Ramesar
Journal:  Bipolar Disord       Date:  2005-06       Impact factor: 6.744

7.  Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization.

Authors:  Yukihiko Iizuka; Yoshitatsu Sei; Daniel R Weinberger; Richard E Straub
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

8.  DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3' end of the gene.

Authors:  Jubao Duan; Maria Martinez; Alan R Sanders; Cuiping Hou; Gregory J Burrell; Aaron J Krasner; Daniel B Schwartz; Pablo V Gejman
Journal:  Hum Hered       Date:  2007-05-02       Impact factor: 0.444

9.  Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2.

Authors:  Jagadeesh S Rao; Renee N Ertley; Stanley I Rapoport; Richard P Bazinet; Ho-Joo Lee
Journal:  J Neurochem       Date:  2007-05-10       Impact factor: 5.372

10.  The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis.

Authors:  Makiko Kishimoto; Hiroshi Ujike; Yasuko Motohashi; Yuji Tanaka; Yuko Okahisa; Tatsuya Kotaka; Mutsuo Harano; Toshiya Inada; Mitsuhiko Yamada; Tokutaro Komiyama; Toru Hori; Yoshimoto Sekine; Nakao Iwata; Ichiro Sora; Masaomi Iyo; Norio Ozaki; Shigetoshi Kuroda
Journal:  Biol Psychiatry       Date:  2007-06-06       Impact factor: 13.382

View more
  2 in total

Review 1.  The role of DNA methylation in the pathophysiology and treatment of bipolar disorder.

Authors:  Gabriel R Fries; Qiongzhen Li; Blake McAlpin; Theo Rein; Consuelo Walss-Bass; Jair C Soares; Joao Quevedo
Journal:  Neurosci Biobehav Rev       Date:  2016-06-18       Impact factor: 8.989

2.  The Genetic Intersection of Neurodevelopmental Disorders and Shared Medical Comorbidities - Relations that Translate from Bench to Bedside.

Authors:  Jasmine T Plummer; Alexis J Gordon; Pat Levitt
Journal:  Front Psychiatry       Date:  2016-08-22       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.